Case Report Takotsubo cardiomyopathy: reversible stress-induced cardiac insult
Tachyarrhtymia induced cardiomyopathy
-
Upload
pavan-rasalkar -
Category
Health & Medicine
-
view
488 -
download
0
Transcript of Tachyarrhtymia induced cardiomyopathy
![Page 1: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/1.jpg)
TACHYCARDIA INDUCED CARDIOMYOPATHY
Dr.Rohit Manoj Kumar
![Page 2: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/2.jpg)
Dilated cardiomyopathy (DCM): Characterized by dilation and impaired contraction of one or both ventricles
DCM - caused by a variety of specific diseases
≥ 50% of patients with DCM: - an etiologic basis will not be
identified - Idiopathic DCM
![Page 3: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/3.jpg)
One series- 1278 patients with congestive heart failure Idiopathic — 51 percent Idiopathic myocarditis — 9 percent Occult coronary disease — 8 percent Other identifiable causes — 32 percent
Felker, et al. The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1,278 patients. Medicine (Baltimore) 1999; 78:270
![Page 4: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/4.jpg)
Clinical presentation Most patients present between age : 20-60 years
- Can occur in children and elderly
Symptoms of CHF Incidental detection of asymptomatic cardiomegaly Symptoms related to coexisting arrhythmia,
conduction disturbance Thromboembolic complications Sudden death
![Page 5: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/5.jpg)
Reversible causes of cardiomyopathy
- Peripartum cardiomyopathy- Tachycardia-mediated cardiomyopathy- Takotsubo cardiomyopathy- Alcoholic cardiomyopathy- Cocaine - Medications- Ischemia- Endocrine dysfunction- SLE, Sarcoidosis- Nutritional deficiencies- Electrolyte abnormalities- Obstructive sleep apnea
![Page 6: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/6.jpg)
Tachycardia induced cardiomyopathy
![Page 7: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/7.jpg)
Introduction Defn: Impairment in left ventricular
function secondary to chronic tachycardia, which is partially or completely reversible once the tachyarrhythmia is controlled
Shown to occur both in experimental models and in patients with incessant tachyarrhythmia.
![Page 8: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/8.jpg)
Fenelon et al proposed the following criteria:
Dilatation of the heart or heart failure
Chronic or very frequent cardiac arrhythmias, including incessant SVTs, AF or AFL and incessant VT
![Page 9: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/9.jpg)
If chronic tachycardia continued more than 10-15% of the day, with an atrial rate of more than 150% of that predicted for age, cardiomyopathy occurs
![Page 10: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/10.jpg)
Types Pure type:
chronic tachycardia causes LV dysfunction in a normal heart and completely recovers after termination
Impure Type: occurs in patients with structural heart diseases,
and cardiac dysfunction may only recover incompletely after termination of the tachycardia
Fenelon et al
![Page 11: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/11.jpg)
Data from several studies and from case reports have shown that rate control by means of cardioversion, negative chronotropic agents, and surgical or catheter-based atrio-ventricular node ablation, resulted in significant improvement of systolic function
Diagnosis is usually made following observation of marked improvement in systolic function after normalization of heart rate
![Page 12: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/12.jpg)
Clinicians should be aware that patients with unexplained systolic dysfunction may have tachycardia-induced cardiomyo-pathy, and that controlling the arrhythmia may result in improvement of systolic function
Exact incidence unclear, an association between tachycardia and cardiomyopathy has been recognized for some time*
*Kasper EK, J Am Coll Cardiol. 1994;23(3):586
![Page 13: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/13.jpg)
Associations SVT: EAT, AF, Afl, AVNRT, AVRT, PJRT
VT: RVOT VT, Fascicular VT
Frequent ectopics: Ventricular, atrial
![Page 14: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/14.jpg)
Pathophysiology Whipple et al. first described
experimental tachycardia-induced cardiomyopathy in 1962
They provided the first experimental model for the condition, demonstrating that rapid and protracted, atrial pacing led to low output heart failure
![Page 15: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/15.jpg)
Proposed mechanisms Myocardial energy depletion
Impaired energy utilization
Ischemia
Abnormal calcium handling
![Page 16: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/16.jpg)
Clinical features AGE:
can occur at any age reported in infants, children, adolescents, and adults
Follows any type of chronic or frequently recurring paroxysmal tachyarrhythmias
Atrial fibrillation, atrial flutter, ectopic atrial tachycardia, atrioventricular tachycardia, and ventricular tachycardia have all been reported to cause
![Page 17: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/17.jpg)
Unclear why some patients with chronic tachyarrhythmia develop ventricular dysfunction whereas others tolerate high rates and maintain normal systolic function
![Page 18: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/18.jpg)
Presumed risk factors include:
Type, rate and duration of tachyarrhythmia
Patient’s age
Underlying heart disease
Drugs
Coexisting medical conditions
![Page 19: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/19.jpg)
Presentation: Variable
Palpitations due to tachycardia per se
Symptoms of heart failure like fatigue, exercise intolerance, dyspnea, pedal edema etc
![Page 20: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/20.jpg)
Relation between AF and HF
![Page 21: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/21.jpg)
Triggers
Atrial Fibrillation
Substrate
![Page 22: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/22.jpg)
![Page 23: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/23.jpg)
Diagnosis
![Page 24: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/24.jpg)
No specific tests or markers available
A high index of suspicion derived from history and clinical features remains the only available tool
Diagnosis should be considered in any patient with left ventricular systolic dysfunction and chronic or frequently recurring cardiac arrhythmia
![Page 25: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/25.jpg)
Evidence of previously normal systolic function, is particularly suggestive of this disorder
Ventricular rate that causes tachycardia-induced cardiomyopathy has not been determined, although any prolonged heart rate greater than 100 beats per minute may be important.
![Page 26: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/26.jpg)
Important to recognize that resting heart rates are poor indicators of overall heart rates in patients with AF
As heart rate response to exercise may vary
Patients with well-controlled resting heart rates may have a rapid ventricular response with minimal activity and develop tachycardia-induced cardiomyopathy
![Page 27: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/27.jpg)
Assessment of exercise heart rates and 24-hour Holter monitoring useful in diagnosing tachycardiomyopathy in patients with AF and ventricular systolic dysfunction
Imaging : ECHO, C MRI
![Page 28: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/28.jpg)
Right ventricular biopsy studies revealed nonspecific findings of varying degrees of cellular hypertrophy and interstitial fibrosis consistent with a nonspecific cardiomyopathy
![Page 29: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/29.jpg)
Treatment
![Page 30: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/30.jpg)
Initial treatment in lines of heart failure: ACEI, B blockers, Diuretics
Heart rate normalization, either by rate or rhythm control, is the cornerstone of therapy
Results in increase in ejection fraction, reduction in end-systolic and end-diastolic volumes and improvement of both symptoms and exercise tolerance
![Page 31: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/31.jpg)
The best means to achieve heart rate control vary
depending on the type of arrhythmia
Include antiarrhythmic drug therapy, external DC
cardioversion, radiofrequency catheter ablation,
pacemaker therapy or insertion of an implantable
cardioverter defibrillator
![Page 32: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/32.jpg)
AF THERAPY
ANTITHROMBOTIC RX
RHYTHMCONTROL
RATECONTROL
OR ?
AND
![Page 33: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/33.jpg)
The AFFIRM Investigators. N Engl J Med. 2002;347:1825-1833.
AFFIRM Trial: Rate vs Rhythm ControlManagement Strategy Trial Design
5-year, randomized, rate control vs. AARx Primary endpoint: overall mortality
Patient population 4060 patients with AF and risk factors for
stroke Minimal symptoms Mean Age = 69 yo Hx of hypertension: 70.8% CAD: 38.2% Enlarged LA: 64.7% Depressed EF: 26.0%
![Page 34: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/34.jpg)
AFFIRM: All-Cause Mortality
Rate N:Rhythm N:
20272033
19251932
18251807
13281316
774780
236255
0
5
10
15
20
25
30
0 1 2 3 4 5
Mor
talit
y, %
RateRhythm
p=0.078 unadjusted
Time (years)
p=0.068 adjusted
The AFFIRM Investigators. N Engl J Med. 2002;347:1825-1833.
![Page 35: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/35.jpg)
100 –
80 –
60 –
40 –
20 –
0 –
Time (years)
PercentWith AFRecurrence
Rate Control
Raitt, et al. Am H J 2006
0 1 2 3 4 5 6
N, Events (%) Rate control: Rhythm control:
563, 3 (0)729, 2 (0)
167, 383 (69)344, 356 (50)
98, 440 (80)250, 422 (60)
42, 472 (87)143, 470 (69)
10, 481 (92)73, 494 (75)
2, 484 (95)18, 503 (79)
Recurrence of AF in Affirm
Rhythm Control
Log rank statistic = 58.62p < 0.0001
![Page 36: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/36.jpg)
Risk of Death in Affirm: Is Sinus Rhythm the Goal?
*HR <1.00: Decreased risk of death, HR >1.00: Increased risk of deathAFFIRM Investigators. Circulation. 2004;109:1509-13.
AFFIRM: Selected time-dependent covariates associated with survival
Sinus rhythm<0.0001
0.53
0.39–0.72Warfarin
<0.0001
0.50
0.37–0.69Digoxin
0.0007
1.42
1.09–1.86Antiarrhythmic 0.0005
1.49
1.11–2.01
CovariateP
Hazard ratio* 99% CI
![Page 37: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/37.jpg)
RACE II Hypothesis: Lenient rate control is not inferior to
strict rate control
Randomly assigned 614 patients with permanent AF to: lenient rate-control strategy (resting heart rate
<110 beats per minute) strict rate-control strategy (resting heart rate
<80 beats per minute and heart rate during moderate exercise <110 beats per minute).
Primary outcome was a composite of death from cardiovascular causes, hospitalization for heart failure, and stroke, systemic embolism, bleeding, and life-threatening arrhythmic events.
No Differerence between Lenient and Strict Rate Control Van Gelder, et.al, for the RACE II Investigators NEJM April 15, 2010, No. 15, Vol 362: 1363-1373
![Page 38: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/38.jpg)
![Page 39: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/39.jpg)
Rate control plusanticoagulation preferred
Rhythm controlpreferred
• No AF symptoms• Long AF Hx• More SHD• Toxicity Risk• Greater risk of
proarrhythmia• Greater AF symptoms• AF compromising LV function• Symptoms despite rate control• Younger age• No or lesser SHD• Rx option of class IC AAD
In anticoagulation candidates, continue anticoagulation indefinitely
APPROACHES TO AF THERAPY
![Page 40: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/40.jpg)
Problems with Meds
Proarrhythmia:
VT with Flecainide, Propafenone in LVH, CAD, Decreased EF
Torsades in Dronedarone, Sotalol, Dofetilide
Organ Toxicity: Amiodarone, procainamide, quinidine Organ Toxicity: Lupus, agranulocytosis,
thrombocytopenia, optic neuritis, pulmonary fibrosis, hepatitis, etc.
![Page 41: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/41.jpg)
ACCF/AHA/HRS 2011 Guidelines Update Treatment of Atrial Fibrillation
*Knight BP. HRS Practical Rate and Rhythm Management of Atrial Fibrillation. Updated January 2010. Available at: http://www.hrsonline.org/ClinicalGuidance/upload/2010_rate-rhythm_guide1.pdf
“In some patients, especially young individuals with very symptomatic AF, ablation may be preferred over years of drug therapy.”*
Maintenance of Sinus Rhythm
DronedaroneFlecainidePropafenoneSotalol Dronedaro
neFlecainidePropafenoneSotalol
CatheterAblation
CatheterAblation
Amiodarone
Amiodarone
CatheterAblation
AmiodaroneDofetilide
AblCatheteration
CatheterAblation
AmiodaroneDofetilide
Substantial LVH
No Yes
DofetilideDronedaroneSotalol
AmiodaroneDofetilide
No (or Minimal)Heart Disease
Hypertension
Coronary Artery Disease
Heart Failure
![Page 42: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/42.jpg)
Prognosis
![Page 43: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/43.jpg)
Recovery of ventricular function after termination of or control of the tachyarrhythmia is extremely variable
Recovery may be complete, partial, or totally absent
The greatest improvement in left ventricular function generally occurs after 1 month of termination or control of arrhytmia
![Page 44: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/44.jpg)
Followed by a slower improvement that reaches its maximum after 6-8months
The gradual time course of recovery of left ventricular function resembles recovery in hibernating myocardium after revascularization and may take up to 1 year
Recovery of function is greater in patients with more profoundly depressed left ventricular function at initial evaluation
![Page 45: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/45.jpg)
Recurrent tachycardia can lead to an abrupt decline in LVEF
Close ongoing monitoring with clinic visits, ambulatory (Holter) monitoring, and echocardiography is essential
Moniter every three to six months for up to one to two years following the initial clinical improvement
![Page 46: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/46.jpg)
In some patients whose LVEF has normalized, the LV chamber may remain somewhat enlarged
If tachycardia-mediated cardiomyopathy recurs, these patients are at substantial risk for sudden death and ICD implantation should be contemplated
![Page 47: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/47.jpg)
Conclusion
![Page 48: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/48.jpg)
Tachycardiomyopathy is a rare but potentially curable form of dilated cardiomyopathy
It should be considered in all patients whose systolic dysfunction is diagnosed subsequent to or concomitant with atrial fibrillation or chronic tachyarrhythmia.
![Page 49: Tachyarrhtymia induced cardiomyopathy](https://reader036.fdocuments.us/reader036/viewer/2022070523/58ecddd81a28abec2f8b46b1/html5/thumbnails/49.jpg)